Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

BACKGROUND: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally to nonhuman primates. It has been shown to be safe a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Kenneth H., Seaton, Kelly E., Huang, Yunda, Grunenberg, Nicole, Isaacs, Abby, Allen, Mary, Ledgerwood, Julie E., Frank, Ian, Sobieszczyk, Magdalena E., Baden, Lindsey R., Rodriguez, Benigno, Van Tieu, Hong, Tomaras, Georgia D., Deal, Aaron, Goodman, Derrick, Bailer, Robert T., Ferrari, Guido, Jensen, Ryan, Hural, John, Graham, Barney S., Mascola, John R., Corey, Lawrence, Montefiori, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685476/
https://www.ncbi.nlm.nih.gov/pubmed/29136037
http://dx.doi.org/10.1371/journal.pmed.1002435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685476/
https://www.ncbi.nlm.nih.gov/pubmed/29136037
http://dx.doi.org/10.1371/journal.pmed.1002435

Ejemplares similares